European patent for our Therapy

Therapy: Publication of the European patent grant. On September 5, 2018, the European Patent Office granted the patent for our therapy with No. EP2783696 “Phosphorylation on the Thr-248 and/or Thr-250 residues of transcription factor E2F4 as a therapeutic target in pathological processes associated with somatic polyploidy”. E.U. Patent No. EP2783696B1…

Eiusmod incididunt reprehenderit ullamco nisi dolore.